Compare ImmunityBio Inc. Common Stock (IBRX) vs Medline Inc. Class A Common Stock (MDLN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ImmunityBio Inc. Common Stock vs Medline Inc. Class A Common Stock — how do they compare? ImmunityBio Inc. Common Stock trades at $9.99 (market cap $10.33B), while Medline Inc. Class A Common Stock trades at $35.75 (market cap $31.10B). The key difference: Medline Inc. Class A Common Stock is far larger — about 3× ImmunityBio Inc. Common Stock's market cap, and ImmunityBio Inc. Common Stock is trading nearer its 52-week high, Medline Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold ImmunityBio Inc. Common Stock for 0 Days and Medline Inc. Class A Common Stock for 0 Days on average.
| IBRX | MDLN | |
|---|---|---|
Market Cap | $10.33B | $31.10B |
Volume | 11,745,198 | 4,471,639 |
Sector | Health | Health |
52-Week High | $11.55 | $49.99 |
52-Week Low | $1.98 | $31.64 |
Typical Hold Time | 0 Days | 0 Days |
Enterprise Value | $10.79B | $41.07B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About ImmunityBio Inc. Common Stock
ImmunityBio develops immune-based therapies for cancer and infectious diseases. Its programs are designed to activate and strengthen the body’s immune response.
Read more on IBRX →About Medline Inc. Class A Common Stock
Medline provides medical-surgical products and supply-chain solutions for healthcare providers. Its portfolio and distribution network serve hospitals, clinics, long-term care facilities, and other care settings.
Read more on MDLN →
